Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025:129:1-16.
doi: 10.1007/978-3-031-97242-3_1.

Cancer Immunotherapy-An Overview

Affiliations
Review

Cancer Immunotherapy-An Overview

Prakash Kulkarni et al. Cancer Treat Res. 2025.

Abstract

Immunotherapy has had a profound impact on how we treat cancer. Immunotherapy takes advantage of the body's immune system to combat the disease and is considered as one of the pillars of cancer care together with chemotherapy, radiation therapy, and surgery. This introductory chapter provides a brief overview of the different types of cancer immunotherapies currently available, their mechanisms of action, and the benefits and potential side effects. Despite the success of these emerging therapies, resistance remains a genuine concern. Thus, mechanisms of resistance to immunotherapy are also briefly discussed. In addition, an overview of the various combination therapies such as chemotherapy, radiation therapy, and targeted therapy, that are currently used in combination with cancer immunotherapy, is presented. Finally, the chapter highlights how a "Team Medicine" approach could enable all eligible cancer patients to receive this promising treatment to treat their respective cancer types. More, detailed information regarding the different immunotherapies as well as their combinations when applicable in different cancers is discussed in the ensuing chapters dedicated to individual cancer type.

Keywords: Cancer immunotherapy; Immunotherapy resistance; Non-genetic mechanisms; Phenotypic plasticity.

PubMed Disclaimer

References

    1. Decker WK, da Silva RF, Sanabria MH, Angelo LS, Guimarães F, Burt BM, Kheradmand F, Paust S. Cancer immunotherapy: historical perspective of a clinical revolution and emerging preclinical animal models. Front Immunol. 2017;8:829. https://doi.org/10.3389/fimmu.2017.00829 . PMID: 28824608. - DOI - PubMed - PMC
    1. Oiseth SJ, Aziz MS. Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead. J Cancer Metastasis Treat. 2017;3:250–61.
    1. Dobosz P, Dzieciątkowski T. The intriguing history of cancer immunotherapy. Front Immunol. 2019;10:2965. https://doi.org/10.3389/fimmu.2019.02965 . PMID: 31921205. - DOI - PubMed - PMC
    1. Eno J. Immunotherapy through the years. J Adv Pract Oncol. 2017;8(7):747–53. Epub 2017 Nov 1. PMID: 30333937. - PubMed - PMC
    1. Abbott M, Ustoyev Y. Cancer and the immune system: the history and background of immunotherapy. Semin Oncol Nurs. 2019;35(5):150923. https://doi.org/10.1016/j.soncn.2019.08.002 . Epub 2019 Sep 13. PMID: 31526550. - DOI - PubMed

LinkOut - more resources